Drug Hunter

📣STARTING NOW Unusual Motifs In Recent Clinical Candidates and Approved Drugs | Join here: https://lnkd.in/g47GVAj8 Friday, July 26 9 AM PDT / 12 PM EDT / 6 PM CEST Join us for an engaging Coffee Chat with our team—Dennis X. Hu, Lewis Pennington, and Dennis Koester—as they delve into intriguing case studies featuring unusual motifs in drug design. Discover how these motifs contribute to molecular innovation and how you can apply this knowledge to your project. The team will also demonstrate how to use the Drug Hunter Structure Search Tool for the Molecule and Drug Database to help you find molecule case studies relevant to you. Don’t miss the chance to interact directly with our team. They will address selected audience questions about the unique motifs covered and would love to hear your thoughts on what structural features you are wondering about.

📣STARTING NOW Unusual Motifs In Recent Clinical Candidates and Approved Drugs | Join here: https://lnkd.in/g47GVAj8 Friday, July 26 9 AM PDT / 12 PM EDT / 6 PM CEST Join us for an engaging Coffee Chat with our team—Dennis X. Hu, Lewis Pennington, and Dennis Koester—as they delve into intriguing case studies featuring unusual motifs in drug design. Discover how these motifs contribute to molecular innovation and how you can apply this knowledge to your project. The team will also demonstrate how to use the Drug Hunter Structure Search Tool for the Molecule and Drug Database to help you find molecule case studies relevant to you. Don’t miss the chance to interact directly with our team. They will address selected audience questions about the unique motifs covered and would love to hear your thoughts on what structural features you are wondering about.

📣STARTING NOW Unusual Motifs In Recent Clinical Candidates and Approved Drugs | Join here: https://lnkd.in/g47GVAj8 Friday, July 26 9 AM PDT / 12 PM EDT / 6 PM CEST Join us for an engaging Coffee Chat with our team—Dennis X. Hu, Lewis Pennington, and Dennis Koester—as they delve into intriguing case studies featuring unusual motifs in drug design. Discover how these motifs contribute to molecular innovation and how you can apply this knowledge to your project. The team will also demonstrate how to use the Drug Hunter Structure Search Tool for the Molecule and Drug Database to help you find molecule case studies relevant to you. Don’t miss the chance to interact directly with our team. They will address selected audience questions about the unique motifs covered and would love to hear your thoughts on what structural features you are wondering about.

Drug-Induced Liver Injury: A Medicinal Chemist’s Perspective | https://lnkd.in/gFRZce4d DILI (drug-induced liver injury) is a leading cause of acute liver failure, accounting for half of these cases and often resulting in drug withdrawals. Understanding and managing DILI risk as a medicinal chemist involves exploring the intricate interplay between properties and structural features. In this article, Anh Tran, Principal Scientist and Medicinal Chemistry Team Leader at Amgen, provides a medicinal chemist's perspective on the current understanding of DILI mechanisms, highlights cutting-edge assay developments for a holistic assessment, and discusses strategies for predicting DILI risks. Ultimately, this article aims to equip medicinal chemists with working knowledge to manage DILI risks in their programs. Full Article: https://lnkd.in/gFRZce4d

📣REMINDER Unusual Motifs In Recent Clinical Candidates and Approved Drugs | https://lnkd.in/gUVfBytM Friday, July 26 9 AM PDT / 12 PM EDT / 6 PM CEST Join us for an engaging Coffee Chat with our team—Dennis X. Hu, Lewis Pennington, and Dennis Koester—as they delve into intriguing case studies featuring unusual motifs in drug design. Discover how these motifs contribute to molecular innovation and how you can apply this knowledge to your project. The team will also demonstrate how to use the Drug Hunter Structure Search Tool for the Molecule and Drug Database to help you find molecule case studies relevant to you. Don’t miss the chance to interact directly with our team. They will address selected audience questions about the unique motifs covered and would love to hear your thoughts on what structural features you are wondering about. We look forward to seeing you on Friday! Register and submit your questions here: https://lnkd.in/gUVfBytM

Genentech’s $100M SHP2 Inhibitor from Relay Therapeutics Now Nixed | https://lnkd.in/gma5_y8F GDC-1971 is an orally bioavailable allosteric inhibitor of the SHP2 phosphatase discovered by Relay Therapeutics and, up until last week, was being developed by Genentech both as a monotherapy and in combination with several anticancer therapies, including their potentially best-in-class KRAS(G12C) inhibitor, divarasib. While the future of this high-priced SHP2 inhibitor remains unclear, it is yet another example of pharmaceutical companies pulling out of SHP2 inhibitor deals. The initial attraction of SHP2 inhibitors was rooted in their potential to combine with numerous classes of clinically important agents including, KRAS inhibitors, PD-1 inhibitors, and receptor tyrosine kinase inhibitors. This article explains why Genentech invested $120M in this now-nixed molecule, includes an overview of SHP2 as an oncology target, details on other disclosed molecules in this space, how GDC-1971 was identified using long-timescale molecular dynamics simulations, what makes it so potent, how GDC-1971’s recent termination aligns with other big pharma moves, and more. Full Article: https://lnkd.in/gma5_y8F

A Selective, State-Independent NaV1.8 inhibitor from Latigo Biotherapeutics | https://lnkd.in/g2Fx_gij Nearly four years ago, when Amgen closed its neuroscience division, several top scientists were recruited to join the nearby fledgling startup, Latigo Biotherapeutics, Inc., whose goal was to build a pipeline of painkillers that could potentially provide a non-addictive alternative to opioids. In February 2024, Latigo emerged from stealth with a whopping $135M in Series A financing, led by Westlake Village BioPartners®, 5AM Ventures, Foresite Capital, and Corner Ventures. Soon thereafter, it published the pharmacological characterization of LTGO-33, a state-independent NaV1.8 inhibitor designed for pain treatment and possessing over 600-fold selectivity over other sodium channels. Latigo has already advanced LTG-001, another NaV1.8 inhibitor, to a Ph. I trial, as well as LTG-4090, which is slated to start a Ph. I trial this year. Check out this article to discover LTGO-33's unique pharmacological properties and what differentiates it from other NaV1.8 inhibitors. Link to article: https://lnkd.in/g2Fx_gij

2023 Drug Approval Highlights | https://lnkd.in/gEzxwQdb Thursday, Aug 1st, 2024 8 AM PDT / 11 AM EDT / 5PM CEST Last year, the FDA green-lit 34 new small molecule drugs, marking a year of significant breakthroughs in drug discovery. Join Dennis X. Hu, Lewis Pennington and Dennis Koester for an engaging Flash Talk that will highlight the most exciting drug discovery stories and deep-dive into the most compelling case studies of small molecule drugs approved in 2023. This session will explore innovative treatments across various disease areas, featuring drugs with fascinating target biology such as ritlecitinib, repotrectinib, omaveloxolone, and pirtobrutinib. During this presentation, our team will provide insights into target rationale, hit finding strategies, lead optimization, and clinical differentiation. The team will highlight noteworthy aspects of each case study, sharing their perspectives on what makes these developments interesting. Attendees are invited to engage with our speakers through a live Q&A session. You can also submit questions prior to the event during the registration process. Don't miss the opportunity to learn from case studies of impactful drugs approved by the FDA in 2023 and discuss transferable insights from these discovery stories. Reserve your spot today! https://lnkd.in/gEzxwQdb

Unusual Motifs In Recent Clinical Candidates and Approved Drugs | https://lnkd.in/gksQUFXj Friday, July 26 9 AM PDT / 12 PM EDT / 6 PM CEST As medicinal chemists, we're all curious about the structures of clinical candidates and drugs. Join us for a Coffee Chat with Dennis X. Hu, Lewis Pennington, and Dennis Koester, where they'll highlight selected unusual motifs in clinical candidates and approved drugs. During this session, they'll discuss case studies leveraging unique motifs, such as azetidines, oxetanes, alkynes, and phosphorus- and boron-containing moieties, and how they impacted the discovery and properties of the molecules. You'll gain transferable insights that you can apply to your own drug discovery programs. They'll also demonstrate how to use Drug Hunter’s new Structure Search tools to generate ideas and pressure-test your designs before synthesis or extensive compound profiling. Additionally, they'll be answering selected audience questions live. If you have any questions prior to the event, please submit them during the registration process. Don't miss this opportunity to expand your knowledge and connect with fellow medicinal chemists. Sign up here to secure your spot in this upcoming Coffee Chat: https://lnkd.in/gksQUFXj

2023 Drug Approval Highlights | https://lnkd.in/gEzxwQdb Thursday, Aug 1st, 2024 8 AM PDT / 11 AM EDT / 5PM CEST Last year, the FDA green-lit 34 new small molecule drugs, marking a year of significant breakthroughs in drug discovery. Join Dennis X. Hu, Lewis Pennington and Dennis Koester for an engaging Flash Talk that will highlight the most exciting drug discovery stories and deep-dive into the most compelling case studies of small molecule drugs approved in 2023. This session will explore innovative treatments across various disease areas, featuring drugs with fascinating target biology such as ritlecitinib, repotrectinib, omaveloxolone, and pirtobrutinib. During this presentation, our team will provide insights into target rationale, hit finding strategies, lead optimization, and clinical differentiation. The team will highlight noteworthy aspects of each case study, sharing their perspectives on what makes these developments interesting. Attendees are invited to engage with our speakers through a live Q&A session. You can also submit questions prior to the event during the registration process. Don't miss the opportunity to learn from case studies of impactful drugs approved by the FDA in 2023 and discuss transferable insights from these discovery stories. Reserve your spot today! https://lnkd.in/gEzxwQdb